Processa Pharmaceuticals Debt To Equity vs. Shares Owned By Insiders

PCSA Stock  USD 0.86  0.02  2.27%   
Based on Processa Pharmaceuticals' profitability indicators, Processa Pharmaceuticals' profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess Processa Pharmaceuticals' ability to earn profits and add value for shareholders.
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
0.01676615
Current Value
0.0159
Quarterly Volatility
1.72046303
 
Credit Downgrade
 
Yuan Drop
 
Covid
At present, Processa Pharmaceuticals' Price To Sales Ratio is projected to increase significantly based on the last few years of reporting. The current year's EV To Sales is expected to grow to 824.68, whereas Days Sales Outstanding is forecasted to decline to 2.61. At present, Processa Pharmaceuticals' Total Other Income Expense Net is projected to increase significantly based on the last few years of reporting. The current year's Non Operating Income Net Other is expected to grow to 3,833, whereas Operating Income is projected to grow to (10.9 M).
For Processa Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Processa Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Processa Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Processa Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Processa Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center.
For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. If investors know Processa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Processa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.25)
Return On Assets
(1.13)
Return On Equity
(2.12)
The market value of Processa Pharmaceuticals is measured differently than its book value, which is the value of Processa that is recorded on the company's balance sheet. Investors also form their own opinion of Processa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Processa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Processa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Processa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Processa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Processa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Processa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Processa Pharmaceuticals Shares Owned By Insiders vs. Debt To Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Processa Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Processa Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Processa Pharmaceuticals is regarded fourth in debt to equity category among its peers. It also is regarded fourth in shares owned by insiders category among its peers making about  8,736  of Shares Owned By Insiders per Debt To Equity. At present, Processa Pharmaceuticals' Debt To Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Processa Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Processa Shares Owned By Insiders vs. Debt To Equity

Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Processa Pharmaceuticals

D/E

 = 

Total Debt

Total Equity

 = 
0 %
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Processa Pharmaceuticals

Insiders Shares

 = 

Executives Shares

+

Employees

 = 
8.74 %
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.

Processa Shares Owned By Insiders Comparison

Processa Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.

Processa Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Processa Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Processa Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Processa Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Processa Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income-11.5 M-10.9 M
Income Before Tax-11.1 M-10.6 M
Net Loss-11.1 M-10.6 M
Total Other Income Expense Net335.5 K352.3 K
Income Tax Expense(2.00)(1.90)
Net Loss-21.7 M-20.6 M
Non Operating Income Net Other3.7 K3.8 K
Net Loss-10.3 M-9.8 M
Net Interest Income326.6 K342.9 K
Interest Income326.6 K342.9 K
Change To Netincome3.6 MM
Net Loss(8.48)(8.91)
Income Quality 0.73  0.68 
Net Income Per E B T 1.10  1.06 

Processa Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Processa Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Processa Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Processa Pharmaceuticals' important profitability drivers and their relationship over time.

Use Processa Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Processa Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Processa Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Processa Pharmaceuticals Pair Trading

Processa Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Processa Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Processa Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Processa Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Processa Pharmaceuticals to buy it.
The correlation of Processa Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Processa Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Processa Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Processa Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Processa Pharmaceuticals position

In addition to having Processa Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Single Stock ETFs Thematic Idea Now

Single Stock ETFs
Single Stock ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Single Stock ETFs theme has 99 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Single Stock ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Processa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Processa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Processa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Processa Pharmaceuticals Stock:
Check out Your Equity Center.
For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
To fully project Processa Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Processa Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Processa Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.
Potential Processa Pharmaceuticals investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Processa Pharmaceuticals investors may work on each financial statement separately, they are all related. The changes in Processa Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Processa Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.